K. Margolin

发表

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

D. Schadendorf, J. Wolchok, F. Hodi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

J. Doroshow, J. Weber, T. Gajewski, 2004, Cancer.

Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma

J. Kirkwood, A. Ribas, M. Milhem, 2018, Clinical Trials.

Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512

V. Sondak, A. Ribas, J. Moon, 2012, PloS one.

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

V. Sondak, J. Sosman, J. Kirkwood, 2012, Clinical Cancer Research.

A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma

D. Gandara, D. Quinn, P. Frankel, 2011, International Journal of Clinical Oncology.

Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial

V. Sondak, J. Sosman, G. Weiss, 1999, Journal of Cancer Research and Clinical Oncology.

Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype

C. Yee, John A Thompson, K. Margolin, 2012, Proceedings of the National Academy of Sciences.

Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

J. Kirkwood, F. Hodi, M. Sznol, 2008 .

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Wei Zhou, Dirk Schadendorf, Reinhard Dummer, 2015, The Lancet. Oncology.

Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial

Y. Yen, J. Doroshow, D. Gandara, 2006, International Journal of Gynecologic Cancer.

Introduction to the role of the immune system in melanoma.

K. Margolin, 2014, Hematology/oncology clinics of North America.

After a treatment breakthrough—progress, plateaus, and raising the bar

K. Margolin, 2017, Cancer.

Response assessment criteria for brain metastases: proposal from the RANO group.

Martin Bendszus, Riccardo Soffietti, Susan M. Chang, 2015, The Lancet. Oncology.

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.

M. Atkins, P. Durani, F. Hodi, 2021, The Lancet. Oncology.

A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.

A. Nademanee, A. Krishnan, M. Slovak, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.

Y. Yen, J. Doroshow, L. Leong, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

E f fects o f I nterleukin-12 o n t he I mmune R esponse t o a Multipeptide V accine f or R esected M etastatic M elanoma

S. Groshen, J. Weber, K. Margolin, 2001 .

Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).

J. Utikal, P. Ascierto, R. Dummer, 2015 .

NCCN clinical practice guidelines in oncology: kidney cancer.

L. Schwartz, R. Figlin, S. Hancock, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.

R. Motzer, M. Harrison, E. Plimack, 2014 .

Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors.

B. Ferrell, P. Frankel, S. Pal, 2013, Clinical Genitourinary Cancer.

Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors

Prakash Kulkarni, R. Salgia, Isa Mambetsariev, 2021, Cancers.

Cancer Immunotherapy Principles and Practice

Ke Liu, Pedro Romero, Patricia A. Young, 2018 .

Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials

Maria L. Wei, A. Marghoob, R. Dellavalle, 2018, Cancer.

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.

D. Schadendorf, P. Ascierto, R. Dummer, 2020, JAMA oncology.

A phase II study of depsipeptide in refractory metastatic renal cell cancer.

W. Stadler, W. McCulloch, John A Thompson, 2006, Clinical genitourinary cancer.

Adjuvant H igh-Dose B olus I nterleukin-2 f or P atients W ith High-Risk R enal C ell C arcinoma: A C ytokine W orking G roup Randomized T rial

R. Figlin, M. Atkins, B. Redman, 2003 .

Shortening the infusion time of anticancer drugs: who will benefit?

M. Gordon, K. Margolin, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression

Y. Yen, J. Doroshow, D. Gandara, 2007, Cancer Chemotherapy and Pharmacology.

Effective salvage therapy for refractory disseminated breast cancer with 5-fluorouracil and high-dose continuous infusion folinic acid.

J. Doroshow, L. Leong, S. Akman, 1988, Advances in experimental medicine and biology.

Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.

J. Doroshow, L. Leong, S. Akman, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.

S. Groshen, Y. Yen, J. Doroshow, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

J. Taube, T. Olencki, E. Lipson, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors.

Y. Yen, J. Doroshow, S. Gaur, 2010, Anticancer research.

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

M. Michaelson, J. Sosman, B. Rini, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor-Infiltrating Lymphocytes in Melanoma

K. Margolin, Sylvia M. Lee, 2012, Current Oncology Reports.

Interleukin-2 and Cancer Therapy

Joseph I. Clark, K. Margolin, 2007 .

Interleukin-2 as Cancer Therapy

Jennifer Hayes Clark, K. Margolin, 2006 .

Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions

P. Brastianos, M. Atkins, H. Tawbi, 2020, Pigment cell & melanoma research.

Ipilimumab in a Phase II trial of melanoma patients with brain metastases

K. Margolin, 2012, Oncoimmunology.

Adoptive T-Cell Therapy of Melanoma Using Designer T-Cell Receptors

K. Margolin, 2011, Current oncology reports.

IL-2 in the therapy of melanoma and other malignancies

K. Margolin, 2009 .

And Now for Something Completely Different: Immunotherapy Beyond Checkpoints in Melanoma.

M. Ross, K. Margolin, I. Glitza, 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk locally advanced/inflammatory and metastatic breast cancer.

J. Doroshow, W. Ye, L. Leong, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CCI‐779 in metastatic melanoma

J. Doroshow, J. Weber, T. Gajewski, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities

V. Sondak, M. Herlyn, M. Atkins, 2019, Pigment cell & melanoma research.

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study

A. Hauschild, D. Schadendorf, R. Gonzalez, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of Metastatic Melanoma in 2018

R. Sullivan, H. Kaufman, K. Margolin, 2018, JAMA oncology.

Phase II study of 4 ′ -deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach

J. Doroshow, L. Leong, S. Akman, 1991, Investigational New Drugs.

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

R. Fisher, M. Atkins, G. Weiss, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.

R. Fisher, J. Sosman, G. Weiss, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.

R. Fisher, M. Atkins, J. Sosman, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN clinical practice guidelines in oncology: testicular cancer.

L. Schwartz, R. Figlin, S. Hancock, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium.

J. Doroshow, L. Leong, S. Akman, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.

J. Doroshow, W. Ye, L. Leong, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group.

A. Nademanee, J. Niland, G. Somlo, 1997, Blood.

Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.

J. Doroshow, L. Leong, G. Somlo, 2000, Gynecologic oncology.

High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.

J. Doroshow, L. Leong, S. Akman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: A Cytokine Working Group (CWG) Study

M. Atkins, J. Sosman, M. Regan, 2013, Journal of immunotherapy.

Kidney cancer: The cytokine working group experience (1986–2001)

M. Atkins, J. Sosman, G. Weiss, 2001, Medical oncology.

Kidney cancer: The cytokine working group experience (1986–2001)

M. Atkins, J. Sosman, G. Weiss, 2001, Medical oncology.

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.

R. Fisher, M. Atkins, J. Sosman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Sunitinib efficacy against advanced renal cell carcinoma.

R. Motzer, M. Michaelson, B. Redman, 2007, The Journal of urology.

Sclerosing Cholangitis after Continuous Hepatic Artery Infusiori of FUDR

M. Kemeny, D. Blayney, H. Battifora, 1985, Annals of surgery.

Fibromyalgia and interleukin-2 therapy for malignancy.

D. Wallace, K. Margolin, P. Waller, 1988, Annals of internal medicine.

Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies.

Y. Yen, L. Leong, P. Frankel, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

M. Atkins, F. Hodi, H. Tawbi, 2018, The New England journal of medicine.

Cellular immunotherapy and autologous transplantation for hematologic malignancy

R. Negrin, S. Forman, K. Margolin, 1997, Immunological Reviews.

Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy.

J. Doroshow, L. Leong, S. Akman, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Advanced Melanoma with Immunological Checkpoint Block

K. Margolin, 2011, Current oncology reports.

Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma

K. Margolin, 2008 .

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

J. Doroshow, M. Sznol, J. Abrams, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas: A trial of the ECOG-ACRIN Cancer Research Group (E2607).

A. Iafrate, J. Kirkwood, T. Kuzel, 2016 .

High‐dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high‐risk primary breast cancer

J. Doroshow, L. Leong, S. Akman, 1994, Cancer.

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.

R. Fisher, M. Atkins, J. Sosman, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Testicular cancer. Clinical practice guidelines in oncology.

P. Kantoff, S. Hancock, R. Motzer, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases.

Jeffrey W. Clark, F. Hodi, M. Sznol, 2010 .

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.

R. Fisher, L. Rubinstein, M. Atkins, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

R. Fisher, M. Atkins, J. Doroshow, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies

F. Marincola, L. Butterfield, P. Srivastava, 2012, Journal of Translational Medicine.

Treatment of Renal Cell Cancer With Programmed Cell Death 1 Blockade: How Much Is Enough?

K. Margolin, 2016, JAMA Oncology.

Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature

N. Tran, H. Tawbi, K. Margolin, 2021, SAGE open medical case reports.

Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel

J. Doroshow, G. Somlo, S. Forman, 2004, Clinical Cancer Research.

Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC).

M. Michaelson, J. Sosman, B. Rini, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

F. Marincola, P. Ascierto, M. Atkins, 2020, Journal for ImmunoTherapy of Cancer.

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

W. Shih, H. Kaufman, D. McDermott, 2020, Frontiers in Oncology.

Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.

M. Maio, K. Margolin, A. D. Di Giacomo, 2010, Seminars in oncology.

Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors

Y. Yen, J. Doroshow, L. Leong, 1996, Cancer Chemotherapy and Pharmacology.

Autologous and allogeneic high-dose therapy for melanoma

K. Margolin, 2001, Current oncology reports.

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

R. Fisher, C. Coltman, J. Doroshow, 1988, Annals of internal medicine.

Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma.

M. Atkins, G. Weiss, M. Sznol, 1989, Cancer treatment reviews.

Phase II Trial of Interleukin 2, Interferon α, and 5-Fluorouracil in Metastatic Renal Cell Cancer: A Cytokine Working Group Study

J. Sosman, G. Weiss, M. Lotze, 2000 .

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.

M. Atkins, J. Doroshow, G. Weiss, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.

M. Atkins, M. Sznol, M. B. Atkins, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Y. Yen, J. Doroshow, L. Leong, 2007, Clinical Cancer Research.

29th Annual meeting of the Society for Immunotherapy of Cancer (SITC)

H. Kohrt, D. Speiser, W. Urba, 2015, Journal of Immunotherapy for Cancer.

A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer

M. Fishman, Y. Yen, J. Doroshow, 2004, Cancer Chemotherapy and Pharmacology.

Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.

J. Doroshow, L. Leong, S. Akman, 1995, Gynecologic oncology.

High‐dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high‐risk primary breast cancer

J. Doroshow, L. Leong, S. Akman, 1994, Cancer.

Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach.

R. Motzer, E. Plimack, D. Feldman, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I study of mitomycin C and menadione in advanced solid tumors

J. Doroshow, L. Leong, S. Akman, 1995, Cancer Chemotherapy and Pharmacology.

Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial.

J. Doroshow, L. Leong, G. Somlo, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.

R. Fisher, G. Weiss, J. Dutcher, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.

E. Hersh, P. Triozzi, J. Rinehart, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.

Y. Yen, J. Doroshow, L. Leong, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.

M. Atkins, F. Hodi, H. Tawbi, 2017 .

Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.

E. Small, B. Rini, W. Stadler, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

M. Atkins, F. Hodi, H. Tawbi, 2019, Journal of Clinical Oncology.

Treatment of metastatic malignant melanoma with trimetrexate: a phase II study.

J. Doroshow, L. Leong, S. Akman, 1990, Medical and pediatric oncology.

Metabolic Checkpoint of Immune Cells in Melanoma Brain Metastases.

K. Margolin, C. Egelston, 2019, Cancer Discovery.

Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.

R. Fisher, M. Bar, G. Weiss, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma.

J. Niland, K. van Besien, G. Somlo, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.

J. Niland, G. Somlo, K. Margolin, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: a phase II trial.

J. Doroshow, L. Leong, S. Akman, 1999, Cancer investigation.

Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial

J. Doroshow, L. Leong, S. Akman, 1995, Journal of Cancer Research and Clinical Oncology.

Mitomycin C and menadione for the treatment of lung cancer: a phase II trial

J. Doroshow, L. Leong, S. Akman, 2004, Investigational New Drugs.

22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma

H. Kohrt, E. Lipson, H. Kluger, 2015 .

A study of radiotherapy modalities combined with continuous 5-FU infusion for locally advanced gastrointestinal malignancies.

Y. Yen, J. Doroshow, L. Leong, 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Adhering to the guidelines: rates of BRCA mutation using NCCN genetic testing criteria

Jaime, Shaheen, J. Kirkwood, 2017 .

Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.

Y. Yen, J. Doroshow, L. Leong, 1998, Cancer research.

Medical Management of Melanoma

K. Margolin, A. Ciurea, 2014 .

Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity

I. Melero, A. De Maria, K. Margolin, 2022, Cells.

NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019.

S. Swetter, M. Ross, J. Sosman, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

M. Atkins, F. Hodi, H. Tawbi, 2021, Neuro-oncology.

Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies.

G. Long, K. Margolin, 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma

M. Atkins, J. Sosman, G. Weiss, 2008, Cancer.

High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome

Y. Yen, J. Doroshow, L. Leong, 2001, British Journal of Cancer.

High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study.

J. Doroshow, L. Leong, B. Carr, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced an

M. Atkins, J. Kirkwood, L. Butterfield, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High‐risk germ cell tumors in men high response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide

J. Doroshow, D. Blayney, K. Margolin, 1993, Cancer.

E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma.

J. Kirkwood, M. Ernstoff, K. Margolin, 2010 .

Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia.

J. Niland, M. Amylon, N. Chao, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.

R. Fisher, J. Sosman, J. Doroshow, 1997, Clinical Cancer Research.

The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC).

R. Figlin, S. Signoretti, M. Atkins, 2010 .

Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial

Y. Yen, J. Doroshow, D. Gandara, 2002, Cancer Chemotherapy and Pharmacology.

Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.

J. Doroshow, L. Leong, G. Somlo, 1999, Gynecologic oncology.

The unique association of malignant histiocytosis and a primary gonadal germ cell tumor.

K. Margolin, T. Traweek, 1992, Medical and pediatric oncology.

Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.

J. Doroshow, L. Leong, G. Somlo, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.

J. Doroshow, L. Leong, S. Akman, 1995, Cancer investigation.

Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.

Y. Yen, J. Doroshow, L. Leong, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Management of advanced germ cell cancer in patients with unfavorable prognosis.

K. Margolin, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis

J. Doroshow, L. Leong, S. Akman, 2000, Cancer Chemotherapy and Pharmacology.

Interleukin-2 in the treatment of renal cancer.

K. Margolin, 2000, Seminars in oncology.

Fulminant Disseminated Intravascular Coagulation as Initial Presentation of BRAF-Mutated Melanoma

K. Margolin, Phyllis Kim, An Uche, 2019, Case reports in oncological medicine.

Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma.

J. Doroshow, L. Leong, S. Akman, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The treatment of brain metastases from malignant melanoma.

K. Margolin, J. Douglas, Kim Margolin, 2002, Seminars in oncology.

Thalidomide as salvage therapy for chronic graft-versus-host disease.

J. Niland, R. Negrin, G. Somlo, 1995, Blood.

Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group

J. Sosman, G. Weiss, M. Ernstoff, 2002, Journal of Cancer Research and Clinical Oncology.

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma.

S. Groshen, J. Weber, K. Margolin, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma

Katie M. Campbell, D. Davar, J. Kirkwood, 2020 .

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

R. Motzer, J. Bacik, M. Mazumdar, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors

V. Velcheti, M. Ernstoff, Jeffrey S. Miller, 2018, Clinical Cancer Research.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Drew M. Pardoll, Janis M. Taube, Paul T. Nghiem, 2016, The New England journal of medicine.

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

Ying S. Ting, R. Govindan, Michael S. Rooney, 2020, Cell.

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

R. Motzer, M. Harrison, E. Plimack, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hepatic metastasis in granulosa cell tumor of the ovary

J. Doroshow, H. Pak, K. Margolin, 1985, Cancer.

High dose chemotherapy and stem cell support in the treatment of germ cell cancer.

K. Margolin, 2003, The Journal of urology.

Review Article HIGH DOSE CHEMOTHERAPY AND STEM CELL SUPPORT IN THE TREATMENT OF GERM CELL CANCER

K. Margolin, 2003 .

Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies

J. Niland, Y. Yen, J. Doroshow, 2003, Cancer Chemotherapy and Pharmacology.

Phase II trial of 5-fluorouracil, high-dose leucovorin calcium, and dipyridamole in advanced prostate cancer

J. Doroshow, L. Leong, S. Akman, 2005, Journal of Cancer Research and Clinical Oncology.

Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin.

J. Doroshow, L. Leong, S. Akman, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer.

J. Doroshow, L. Leong, S. Akman, 1992, Cancer research.

3-Deazaguanine: Report of a phase I trial and drug-related cardiac toxicity

J. Doroshow, L. Leong, S. Akman, 1990, Investigational New Drugs.

Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology.

J. Berzofsky, R. DePinho, P. Wen, 2020, Neuro-oncology.

Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.

Renato Martins, Colin C Pritchard, Stephen J Salipante, 2014, The Journal of molecular diagnostics : JMD.

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

D. Schadendorf, P. Ascierto, R. Dummer, 2017, European journal of cancer.

Cytokines in Cancer Immunotherapy

K. Margolin, Kim Margolin, Sylvia Lee, 2011, Cancers.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

V. Sondak, R. Sullivan, M. Atkins, 2018, Journal of Immunotherapy for Cancer.

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

R. Fisher, M. Atkins, G. Weiss, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.

R. Motzer, E. Jonasch, T. Choueiri, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Inside life of melanoma cell signaling, molecular insights, and therapeutic targets

J. Sosman, K. Margolin, 2009, Current oncology reports.

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

M. Atkins, J. Kirkwood, L. Butterfield, 2017, Clinical Cancer Research.

Targeting the mTOR, PI3K, and AKT Pathways in Melanoma

K. Margolin, 2012 .

Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer

J. Waisman, J. Mortimer, Yinghui Huang, 2022, JCI insight.

Inhibition of vascular endothelial growth factor in the treatment of solid tumors

K. Margolin, 2002, Current oncology reports.

Hemorrhagic collision metastasis in a cerebral arteriovenous malformation

C. Keene, L. Kim, K. Margolin, 2014, Journal of NeuroInterventional Surgery.

The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma

R. Figlin, A. Belldegrun, Su-Chun Cheng, 2014, Clinical Cancer Research.

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

J. Wolchok, F. Hodi, M. Sznol, 2012, The Lancet. Oncology.

Sunitinib in patients with metastatic renal cell carcinoma.

R. Motzer, J. Bacik, M. Michaelson, 2006, JAMA.

Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.

R. Fisher, M. Atkins, G. Weiss, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression

Peter P. Lee, J. Mortimer, J. Yim, 2018, Nature Communications.

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

R. Figlin, M. Atkins, B. Redman, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy

H. Tawbi, H. Kluger, K. Margolin, 2019, Cutaneous Melanoma.

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

M. Atkins, J. Sosman, J. Kirkwood, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Methodologic guidelines for the design of high-dose chemotherapy regimens.

J. Doroshow, K. Margolin, J. Longmate, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

P. Ascierto, K. Margolin, 2014, Cancer.

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

V. Sondak, M. Atkins, J. Sosman, 2013, Nature Reviews Clinical Oncology.

Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.

Andrew Kramar, Caroline Bascoul-Mollevi, Christophe Massard, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma and Other Cutaneous Malignancies

V. Sondak, K. Margolin, 2003 .

Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

J. Kirkwood, A. Chen, D. Gandara, 2011, Clinical Cancer Research.

Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

F. Marincola, P. Ascierto, G. Ciliberto, 2013, Journal of translational medicine.

Cytokine Therapy.

K. Margolin, A. Silk, 2019, Hematology/oncology clinics of North America.

Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.

M. Atkins, T. Crocenzi, J. Fisher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

G. Sledge, S. Shak, R. Benjamin, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

J. Breed, W. Novotny, E. Holmgren, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.

J. Doroshow, D. Gandara, H. Lenz, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting Vascular Endothelium with Antibodies

K. Margolin, P. Twardowski, 2002 .

Melanoma central nervous system metastases: current approaches, challenges, and opportunities

R. White, P. Wen, P. Brastianos, 2016, Pigment cell & melanoma research.

Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications

K. Margolin, K. Grossmann, 2015, Therapeutic advances in medical oncology.

Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer

Y. Yen, J. Doroshow, D. Gandara, 2004, Cancer Chemotherapy and Pharmacology.

Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.

Y. Nieto, L. Pagliaro, S. Tu, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.

T. Powles, C. Bascoul-Mollevi, L. Einhorn, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.

R. Gray, M. Citron, N. Robert, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

V. Sondak, M. Ross, M. Atkins, 2023, The New England journal of medicine.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

V. Sondak, J. Taube, M. Ross, 2019, The Lancet. Oncology.

NCI 8628: A randomized phase 2 study of ziv‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma

J. Kirkwood, A. Chen, H. Tawbi, 2018, Cancer.

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Eudocia Q Lee, Martin Bendszus, Gordon J Harris, 2018, The Lancet. Oncology.

Polymicrobial enteric septicemia from coffee enemas.

K. Margolin, M. Green, 1984, The Western journal of medicine.

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG‐ACRIN Cancer Research Group (E2607)

J. Kirkwood, T. Kuzel, D. Lawrence, 2017, Cancer.

Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.

A. Nademanee, J. Niland, A. Krishnan, 2000, Clinical lymphoma.

Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.

A. Nademanee, A. Krishnan, G. Somlo, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effect of CD34 " Selection and Various Schedules of Stem Cell Reinfusion and Granulocyte Colony-Stimulating Factor Priming on Hematopoietic Recovery After High-Dose Chemotherapy for Breast Cancer

J. Doroshow, L. Leong, T. Odom-Maryon, 1997 .

Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.

J. Doroshow, L. Leong, T. Odom-Maryon, 1997, Blood.

T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.

J. Wolchok, P. Greenberg, C. Yee, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytokines in the Treatment of Cancer

H. Kaufman, K. Margolin, M. Lazarus, 2013 .

Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient

J. Wolchok, P. Greenberg, C. Yee, 2016, The Journal of experimental medicine.

High‐Titer, High‐Thermal‐Amplitude Cold Autoagglutinin Not Associated with Hemolytic Anemia

K. Margolin, I. Sniecinski, D. Branch, 1988, Vox sanguinis.

Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases

P. Ascierto, J. Wolchok, I. Puzanov, 2013 .

A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States

G. Linette, J. Hainsworth, K. Flaherty, 2014, Cancer journal.

BRAF inhibition and beyond in advanced melanoma

K. Margolin, 2012, The Lancet.

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.

S. Swetter, M. Ross, J. Sosman, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases.

N. Ramakrishna, K. Margolin, 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

Susan M. Chang, P. Brown, M. Mehta, 2013, The Lancet. Oncology.

Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2016 .

The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma

K. Margolin, 2016, Current Treatment Options in Oncology.

Immune checkpoint blockade in patients with melanoma metastatic to the brain.

K. Margolin, A. D. Di Giacomo, 2015, Seminars in oncology.

Disparate clinical activity of PD‐1 blockade in melanoma subtypes: Know thy enemy!

K. Margolin, S. Bhatia, 2016, Cancer.

Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

H. Tawbi, C. Chung, K. Margolin, 2018, The New England journal of medicine.

Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma

A. Amini, V. Parekh, C. Di Raimondo, 2020, JAAD case reports.

Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.

R. Fisher, M. Atkins, J. Sosman, 1997, The cancer journal from Scientific American.

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).

J. Manola, K. Flaherty, M. Atkins, 2015, Journal of Clinical Oncology.

High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study.

A. Nademanee, K. Margolin, G. M. Schmidt, 1992, Blood.

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.

V. Sondak, J. Sosman, G. Weiss, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vaccination of Metastatic Colorectal Cancer Patients With Matured Dendritic Cells Loaded With Multiple Major Histocompatibility Complex Class I Peptides

B. Kavanagh, M. Lotze, A. Venook, 2007, Journal of immunotherapy.

A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b.

M. Atkins, G. Weiss, J. Sparano, 1990, Journal of biological response modifiers.

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.

B. LaFleur, M. Atkins, J. Sosman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updates in the management of brain metastases.

Eudocia Q Lee, Brian M Alexander, Riccardo Soffietti, 2016, Neuro-oncology.

Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling

A. Amini, V. Parekh, M. O'Leary, 2020, Annals of Surgical Oncology.

A Cytokine Working Group (CWG) 3-arm phase II trial of gp100 (209–2M) peptide + high dose (HD) Interleukin-2 (IL-2) in HLA-A2+ (A2+) advanced melanoma patients (pts)

Jeffrey W. Clark, M. Atkins, J. Sosman, 2005 .

Sun exposure and mortality from melanoma

K. Margolin, 2006 .

Testicular cancer.

P. Kantoff, S. Hancock, R. Motzer, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Melanoma's deadly march to the brain

J. Moon, M. Othus, K. Margolin, 2011, Cancer.

A Phase II Clinical Trial of Interleukin‐2 and Lymphokine‐Activated Killer Cells in Advanced Colorectal Carcinoma

R. Fisher, M. Atkins, J. Doroshow, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Dolastatin-10 in Metastatic Melanoma: A Phase II and Pharmokinetic Trial of the California Cancer Consortium

J. Doroshow, D. Gandara, R. Gonzalez, 2004, Investigational New Drugs.

Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).

R. Motzer, M. Harrison, E. Plimack, 2015 .

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

M. Atkins, J. Sosman, M. Ernstoff, 2007, Clinical Cancer Research.

Biochemotherapy for melanoma

K. Margolin, 2004, Cancer.

Apheresis techniques in lymphokine‐activated killer cell production

K. Margolin, I. Sniecinski, B. Mills, 1988, Journal of clinical apheresis.

Cytokine therapy in cancer

K. Margolin, 2008, Expert opinion on biological therapy.

Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies

Y. Yen, J. Doroshow, L. Leong, 2004, Cancer Chemotherapy and Pharmacology.

Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man.

J. Doroshow, S. Textor, D. Blayney, 1987, The American journal of medicine.

NCCN Kidney Cancer Clinical Practice Guidelines in Oncology

S. Hancock, R. Motzer, E. Jonasch, 2011 .

High-Dose R ecombinant I nterleukin 2 T herapy f or P atients With M etastatic M elanoma: A nalysis o f 2 70 P atients Treated B etween 1 985 a nd 1 993

R. Fisher, M. Atkins, G. Weiss, 1999 .

Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy

J. Doroshow, L. Leong, S. Akman, 2005, Investigational New Drugs.

Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.

R. Fisher, J. Doroshow, G. Weiss, 1989, Journal of the National Cancer Institute.

Kidney Cancer

S. Hancock, R. Motzer, E. Jonasch, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.

R. Fisher, J. Sosman, G. Weiss, 1997, The cancer journal from Scientific American.

A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma.

M. Atkins, J. Sosman, J. Doroshow, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.

R. Fisher, M. Atkins, J. Doroshow, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Phase I/II Trial of Outpatient PEG-interferon With Interleukin-2 in Advanced Renal Cell Carcinoma: A Cytokine Working Group Study

M. Atkins, J. Sosman, M. Ernstoff, 2007, Journal of immunotherapy.

PHASE I TRIAL OF ALT-803, A NOVEL RECOMBINANT INTERLEUKIN-15 COMPLEX, IN PATIENTS WITH ADVANCED SOLID TUMORS

V. Velcheti, M. Ernstoff, Jeffrey S. Miller, 2018 .

Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies

C. Tangen, E. Crawford, D. Quinn, 2006, Cancer.

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

Tianhong Li, Sanjiv S. Agarwala, Scott D. Christensen, 2010, Investigational New Drugs.

Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors

Yun Yen, James H. Doroshow, Adam Mamelak, 2010, Cancer Chemotherapy and Pharmacology.

Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.

S. Vuk-Pavlović, Y. Yen, J. Doroshow, 1999, Blood.

Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer

J. Doroshow, L. Leong, P. Frankel, 2002, British Journal of Cancer.

Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

Y. Yen, L. Leong, G. Somlo, 2001, Bone Marrow Transplantation.

Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology.

P. Brastianos, K. Margolin, Helena A. Yu, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real‐time reverse transcription‐PCR vs. Relative quantification reverse transcription‐PCR utilizing DNA sequencer analysis of PCR products

Y. Yen, J. Doroshow, D. Gandara, 2003, Journal of clinical laboratory analysis.

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy

Shannon C. Trotter, J. Stein, R. Dellavalle, 2017, Melanoma management.

Healthcare Resource Utilization and Associated Costs in Patients with Advanced Melanoma Receiving First-Line Ipilimumab

S. Corman, M. Botteman, K. Margolin, 2015 .

Oligometastatic Breast Cancer Patients Treated with High-Dose Chemotherapy and Targeted Radiation: Long-Term Follow-Up of a Phase II Trial

A. Amini, L. Leong, P. Frankel, 2022, Cancers.

Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin.

J. Kirkwood, P. Frankel, K. Margolin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab

Katie M. Campbell, D. Davar, J. Kirkwood, 2020, Journal of Immunotherapy for Cancer.

An open‐label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer

G. Hortobagyi, H. Rugo, W. Urba, 2012, Cancer.

A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A

Y. Yen, J. Doroshow, L. Leong, 2000, Cancer Chemotherapy and Pharmacology.

LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer

A. El-Khoueiry, S. O’Day, A. Tsimberidou, 2022, Annals of Oncology.

Pathologic complete response with radiation and vismodegib in a patient with advanced basal cell carcinoma: A case report

A. Amini, V. Parekh, K. Margolin, 2021, Molecular and clinical oncology.

Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB.

M Mazumdar, R. Motzer, J. Bacik, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab plus ipilimumab in melanoma brain metastases - Authors' reply.

H. Tawbi, C. Anders, K. Margolin, 2022, The Lancet. Oncology.

Fluorouracil and leucovorin in advanced breast cancer.

J. Doroshow, L. Leong, S. Akman, 1993, Advances in experimental medicine and biology.

Oblimersen and α-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium

D. Gandara, D. Quinn, P. Frankel, 2007, Journal of Cancer Research and Clinical Oncology.

Phase II trial of 5-fluorouracil and high-dose folinic acid as first- or second-line therapy for advanced breast cancer.

S. Green, J. Doroshow, L. Leong, 1994, American journal of clinical oncology.

Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients.

L. Einhorn, A. Necchi, A. Kramar, 2010 .

Kidney cancer. Clinical practice guidelines in oncology.

P. Kantoff, S. Hancock, R. Motzer, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States

M. Ernstoff, A. Dowlati, K. Margolin, 2021, ESMO open.

A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma

Jeffrey W. Clark, M. Atkins, J. Sosman, 2005 .

Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.

Y. Yen, J. Doroshow, L. Leong, 2004, Journal of Clinical Oncology.

Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea

J. Doroshow, L. Leong, S. Akman, 2004, Cancer Chemotherapy and Pharmacology.

A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer.

M. Goldstein, R. Gaynor, P. Ott, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Kidney cancer, version 2.2014.

S. Hancock, R. Motzer, E. Jonasch, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933

V. Sondak, B. Redman, A. Ribas, 2015, Cancer.

The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC).

J. Manola, K. Flaherty, M. Atkins, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies.

Su-Chun Cheng, S. Signoretti, B. Leibovich, 2013 .

Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma.

R. Fisher, M. Atkins, J. Doroshow, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Abstract CT125: A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broadde novoanti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer

M. Goldstein, R. Govindan, R. Gaynor, 2018, Clinical Trials.

950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma

D. Davar, J. Kirkwood, A. Ribas, 2021, Journal for ImmunoTherapy of Cancer.

Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases.

F. Hodi, J. Thompson, A. Pavlick, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Control of experimental melanoma by host CXCR2

K. Margolin, 2009, Current oncology reports.

KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.

K. Emancipator, C. Blank, I. Puzanov, 2016 .

Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.

J. Doroshow, D. Gandara, H. Lenz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The NCCN Kidney Cancer Clinical Practice Guidelines in OncologyTM

L. Schwartz, R. Figlin, S. Hancock, 2009 .

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study

Y. Yen, J. Doroshow, D. Gandara, 2009, Cancer Chemotherapy and Pharmacology.

Brain Metastases in Melanoma: Moving Toward Curing the Incurable.

K. Margolin, 2016, Journal of oncology practice.

Reply to A. Shinde et al.

H. Tawbi, H. Kluger, G. Long, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hemorrhagic collision metastasis in a cerebral arteriovenous malformation

C. Keene, L. Kim, K. Margolin, 2014, BMJ Case Reports.

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

J. Sosman, A. Ribas, P. Scumpia, 2023, Nature Medicine.

Lidocaine for severe hiccups.

K. Margolin, M. Dunst, D. Horak, 1993, The New England journal of medicine.

The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.

A. Nademanee, J. Niland, G. Somlo, 1995, Blood.

Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission

M. Amylon, M. Slovak, R. Negrin, 1999, Leukemia.

Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers

M. Michaelson, J. Sosman, B. Rini, 2007 .

Kidney Cancer.

L. Schwartz, R. Figlin, S. Hancock, 2009, Cancer journal.

CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium

J. Doroshow, J. Weber, T. Gajewski, 2004 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

V. Sondak, J. Sosman, J. Kirkwood, 2012, Clinical Cancer Research.

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

P. Ascierto, F. Hodi, M. Sznol, 2015, Journal of Immunotherapy for Cancer.

M. Atkins, T. Crocenzi, J. Fisher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

P. Ascierto, K. Margolin, 2014, Cancer.

Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.

M. Maio, K. Margolin, A. D. Di Giacomo, 2010, Seminars in oncology.

Response assessment criteria for brain metastases: proposal from the RANO group.

Susan M. Chang, P. Brown, M. Mehta, 2015, The Lancet. Oncology.

NCCN clinical practice guidelines in oncology: testicular cancer.

L. Schwartz, R. Figlin, S. Hancock, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

J. Sosman, D. Morton, A. Pavlick, 2013, Nature Reviews Clinical Oncology.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

J. Taube, T. Olencki, E. Lipson, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sentinel-node biopsy or nodal observation in melanoma.

K. Margolin, 2007, Current oncology reports.

CCR9:CCL25 in melanoma metastatic to small intestine

K. Margolin, 2009, Current oncology reports.

Sentinel node biopsy or nodal observation

K. Margolin, 2007 .